Mid-cap biotechs best larger companies to emerge as 2014's growth kings
- A new report from GlobalData finds that mid-sized biotechs bested their larger biopharma cousins in one key respect: revenue growth.
- Combined revenues for 35 mid-sized biotechs increased 21.9% in 2014, according to the report. Much of that growth was driven by two companies—Regeneron and Alexion.
- The overall increase in total revenues for this group of companies increased from $24.8 billion to $26.5 billion.
Overall, the mid-sized biotechs have demonstrated a lot of agility. Growth has been driven in large part by having a top-selling drug, such as Regeneron's Eylea or Alexion's Soliris. Factors that have been helpful include expanding sales beyond domestic borders and partnering with larger companies.
On the other side of the partnership equation, larger companies are noting the opportunity associated with mid-sized companies. For examples, AbbVie recently agreed to buy Pharmacyclics for $21 billion. Mid-cap companies are continuing to grow rapidly, and it looks as if 2015 will be another good year for this sector.